Revenio iCare DRSplus joins iHealthScreen’s FDA-cleared AI diabetic retinopathy screening solution

• Revenio partnered with iHealthScreen to integrate iCare DRSplus imaging into the FDA 510(k)-cleared iPredict-DR AI diabetic retinopathy screening software.
• U.S. rollout targets primary care, using automated image analysis to flag patients needing referral for diabetic retinopathy evaluation.
• Marks iCare DRSplus’ first inclusion in an FDA-cleared AI screening solution in the U.S., supporting Revenio’s push into AI-enabled eye diagnostics.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revenio Group Oyj published the original content used to generate this news brief on August 17, 2026, and is solely responsible for the information contained therein.